Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Home Depot won't hike prices in response to tariffs, Q1 sales fall

(Sharecast News) - US do-it-yourself chain Home Depot on Tuesday held full-year sales forecasts and said it did not expect to raise prices in response to President Donald trump's tariffs. The company said it expected total sales to grow by 2.8% and comparable sales 1%. First-quarter earnings per share came in at $3.56 adjusted compared with expectations of $3.60 and revenue was $39.86bn against vs. $39.31bn expected by analysts.

Its forecast is based on the continuation of a U.S. agreement to temporarily lower tariffs to 30% on imports from China and to 10% for many other countries.

In the three months to May 4 net income fell to $3.43bn from $3.6bn a year earlier.

"Because of our scale, the great partnerships we have with our suppliers and productivity that we continue to drive in our business, we intend to generally maintain our current pricing levels across our portfolio," chief financial officer Richard McPhail told CNBC in an interview.

he added that more than half of what the company sells comes from the US and had worked to diversify the source of imports over the past several years, including cutting back on those from China.

By this time next year, no single country outside of the US will represent more than 10% of the company's purchases, he said.

Home Depot's pricing strategy is at odds with Walmart, which said last week that it would have to raise prices as soon as late May to cover higher costs from tariffs.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.